key: cord-0968268-mingrasy authors: Hsieh, Yu-Ting; Tsai, Tsung-Lin; Tu, Chia-Chun; Huang, Shen-Yan; Heng, Jian-Wen; Tsai, Pei-Yuan; Chao, Tai-Ling; Tsai, Ya-Min; Chang, Pei-Ching; Lee, Chien-Kuo; Yu, Guann-Yi; Chang, Sui-Yuan; Dzhagalov, Ivan L.; Hsu, Chia-Lin title: Equilibrative Nucleoside Transporter 3 is an IFN-stimulated Gene that Facilitates Viral Genome Release date: 2022-04-28 journal: bioRxiv DOI: 10.1101/2022.04.27.489746 sha: 0794ad2a73e6a04dac8aaed12acaebc5268e6850 doc_id: 968268 cord_uid: mingrasy An increasing body of evidence emphasizes the role of metabolic reprogramming in immune cells to fight off infections. However, little is known about the regulation of metabolite transporters that facilitate and support metabolic demands. In this study, we found that equilibrative nucleoside transporter 3 (ENT3) expression is part of the innate immune response, and is rapidly upregulated upon bacterial and viral infection. The transcription of ENT3 is directly under the regulation of IFN-induced signaling, positioning this metabolite transporter as an Interferon-stimulated gene (ISG). Moreover, we unveil that several viruses, including SARS-CoV2, require ENT3 to facilitate their entry into the cytoplasm. The removal or suppression of ENT3 expression is sufficient to significantly decrease viral replication in vitro and in vivo. Upon infection, the immune system must recognize the threat to initiate 39 necessary responses, remove the insults, and regain homeostasis. The fast-40 acting innate immunity is responsible for the initial recognition and early 41 responses and is vital to recruit antigen-specific adaptive immunity. The 42 longstanding co-evolution between the immune system and pathogens has 43 driven innate immune cells to generate various arsenals fighting off the 44 pathogens; on the other hand, the pathogens also continuously develop 45 numerous ways to hide from or interfere with the immune responses. Once the 46 pathogen invasion is established, responding cells shift from quiescence to 47 As one of the most well-studied pathogen-associated-molecular-patterns 168 (PAMPs), LPS is known for its ability to trigger the expression of inflammatory 169 cytokines and the maturation of immune cells. The LPS-mediated signaling can 170 be divided into MyD88-dependent and -independent (or TRIF-dependent) 171 pathways (Lu et al, 2008) (Fig 2A) . To identify the pathway that regulates Slc29a3 172 expression upon LPS stimulation, we treated MyD88-deficient BMDMs with LPS 173 or E. coli and monitored the mRNA level of Slc29a3. We found that both 174 treatments effectively stimulated the upregulation of Slc29a3 in MyD88 -/-BMDMs, 175 suggesting that MyD88 is dispensable for the LPS-induced Slc29a3 expression 176 Slc29a3 is an unidentified ISGs, we treated STAT1 -/-BMDMs with LPS, E. coli, or 204 IFN-β but none of them could induce the expression of Slc29a3 (Fig 3C) . The 205 IFN family is comprised of two major classes of related cytokines -type I and 206 type II IFNs. Harboring antiviral activities, the only type II IFN, IFN-γ, does not 207 have marked structural homology to type I IFNs and interacts with a different type 208 II receptor (IFNGR) (Platanias, 2005) . To test the effects of major IFNs on 209 Slc29a3 induction, we treated BMDMs with different doses of IFNs and profiled 210 the expression of Slc29a3. We found that both type I IFNs, IFN-α ( Fig 3C) and 211 IFN-β (Fig 3D) , are effective inducers for Slc29a3 expression, and the induction 212 peaked rapidly at 4 hours upon stimulation and remained above the resting level 213 at least for 48 hours. On the other hand, IFN-γ elicited only moderate 214 upregulation of Slc29a3 at later time points (Fig 3E) . These results suggest that 215 the transcription of Slc29a3 is likely a direct downstream target of type I IFN-216 IFNAR signaling event. Moreover, these findings strongly imply that the 217 metabolite transporter, ENT3, might be an unrecognized ISG. 218 Upon sensing the pathogen and the production of IFNs, hundreds of ISGs are 221 transcribed to arm the infected and nearby cells to an antiviral state -including 222 enhanced detection of pathogens and initiation of the pathogen removal 223 machinery. Although a variety of genes comprises ISGs, they share the common 224 goal of combating the pathogen and regaining homeostasis (Schneider et al, 225 2014) . To explore the possibility that ENT3 is an ISG, we extracted the results 226 from the microarray datasets curated in the INTERFEROME database 227 (http://www.interferome.org/interferome/home.jspx). We found that Slc29a3 is 228 upregulated to the same level as other validated positive regulators and antiviral effector ISGs in response to IFN-β treatment (Fig 4A) , further supporting the 230 notion that Slc29a3 is one of the Interferon-regulated genes (IRGs). To 231 investigate if a direct interaction between the IFNAR-STAT1 pathway and 232 Slc29a3 expression at the transcriptional level exists, we searched the ChIP-233 Atlas database (http://chip-atlas.org/), which curated ChIP-seq data for potential 234 STAT1 binding sites on Slc29a3 gene locus. We identified three potential STAT1 235 binding sites in the promoter and 3' untranslated region (UTR) of Slc29a3 from 236 the database search ( Fig 4B) . To confirm this result, we performed ChIP-qPCR 237 on IFN-β treated BMDMs (Supplemental Fig 3) , and clear STAT1 binding was 238 found in the Slc29a3 promoter region (Fig 4E) . In contrast, no statistically 239 significant differences were found in the two additional potential STAT1 binding 240 sites within the 3' UTR compared with untreated control (Fig 4C, D) . Together, 241 these results support the idea that ENT3 is an ISG under the direct regulation of 242 the IFN-β-STAT1 pathway. Both EMCV and EV71 are small non-enveloped RNA virus belonging to 252 Picornaviridae. EMCV is known to cause myocarditis and encephalitis in mice, 253 while EV71 infection is the common cause of human's hand, foot, and mouth 254 disease (HFMD). We observed EMCV infection increased the transcription of 255 Slc29a3 in BMDMs (Fig 5A) . THP-1 derived human macrophages also 256 responded to the EV71 challenge by the upregulation of Slc29a3 (Fig 5B) . To 257 confirm these observations, we challenged BMDMs with Poly I:C, the synthetic 258 mimetic of a double-stranded RNA capable of stimulating the immune system 259 through the TLR and RLR families that drives potent type I IFN responses. Poly I:C stimulation effectively induced the expression of Slc29a3 in BMDMs (Fig 5C) . 261 Together, these results demonstrate that the upregulation of ENT3 in 262 macrophages is an early response to viral invasion. While it is well known that 263 ISGs are synergistic in blocking virus entry and inhibiting viral translation and 264 replication, the role of ENT3 as an ISG upon viral infection is unclear. To study 265 the participation of ENT3 in antiviral response in vivo, Cx3cr1-cre ENT3 fl/fl mice 266 were challenged with EMCV. To our surprise, the Cx3cr1-cre ENT3 fl/fl mice were 267 more resistant to the EMCV-induced lethality and showed better survival (Fig 268 5D ). In agreement with the survival curve, the Cx3cr1-cre ENT3 fl/fl mice exhibited 269 clearly milder encephalitis phenotype (Fig 5E) . We performed the plaque assay The lower viral loads in Cx3cr1-cre ENT3 fl/fl mouse may have two possible 278 explanations: the ENT3-deficient mouse had hyper-activated IFN responses that 279 rapidly cleared the viruses, or the defect in ENT3 impacted viral replication. To 280 probe these two possibilities, we infected BMDMs with EMCV in vitro and 281 followed BMDMs' IFN response. We found that upon EMCV infection, ENT3 -/-282 BMDMs had significantly lower IFN-β production than WT (Fig 6A) , suggesting 283 that ENT3 -/-BMDMs do not have a hyperactive antiviral response. To explore if 284 this result was due to the altered cytosolic innate sensing in the absence of 285 ENT3, we introduced poly I:C, the long synthetic analog of dsRNA, via liposome 286 into BMDMs. We found a lower IFN-β expression upon liposome-mediated poly 287 I:C challenge in ENT3 -/-BMDMs compared with WT, suggesting the cytosolic 288 RNA helicases retinoic acid-inducible protein I (RIG-I) and melanoma 289 differentiation-associate gene 5 (MDA-5) modules may be hypo-functional (Fig 290 6B ). These results rule out the hyperactive IFN responses in ENT3 -/-291 macrophages instead argues for the role of ENT3 in EMCV replication. By 292 measuring the transcription of EMCV viral protein 2A2B, we found the EMCV 293 replication was almost completely abolished in ENT3 -/-BMDMs ( Fig 6C) . As 294 metabolite transporter, we speculated that ENT3 might be an ISG involved with 295 the regulation of macrophage cellular metabolism. Macrophages undergo 296 metabolic reprogramming upon infection to support their effector functions; on 297 the other hand, viruses also actively manipulate host cell metabolism to establish 298 an optimal environment for their propagation. To evaluate if ENT3 -/-BMDMs are 299 metabolically distinct from WT BMDMs, we applied the proton efflux assays to 300 measure the glycolytic and mitochondrial activities. The results showed no 301 differences in OCR ( Fig 6D) yet significantly higher ECAR in ENT3 -/-BMDMs 302 compared with WT ( Fig 6E) , suggesting that the abolished viral replication in 303 ENT3 -/-BMDMs is unlikely due to defective glycolytic or mitochondrial activities of 304 BMDMs. However, upon activation-induced metabolic reprogramming process, 305 BMDMs defective in ENT3 function may have disturbances in metabolic 306 pathways other than glycolysis. To explore this possibility, we treated WT and 307 ENT3 -/-BMDMs with IFN-β and performed RNAseq analyses. Interestingly, but 308 not unexpectedly, GSEA on KEGG pathways revealed the strong association of 309 nucleotide-related activities, including DNA replication, nucleotide excision repair, 310 and pyrimidine metabolism in ENT3 -/-BMDMs compared with the WT group (Fig 311 6F ). The increased nucleotide excision repair and pyrimidine metabolism implied 312 the disturbed nucleoside/nucleotide supply in ENT3 -/-BMDMs. These 313 observations prompted us to hypothesize that ENT3 may have an essential role 314 in providing increased pools of free nucleotides necessary for rapid viral genome 315 replication. To test this possibility, we challenged ENT3 -/-BMDMs with EMCV 316 and measured the viral replication in the absence or presence of ribonucleosides 317 (rN) supplements. We noted that the addition of rN did salvage the viral 318 replication in ENT3 -/-BMDMs in a dose-dependent fashion ( Fig 6G) ; however, 319 the rescue effect on viral replication is minute compared to WT BMDMs without 320 rN addition. These results suggest that although ENT3 deficiency impacts the nucleotides pool to support viral replication, ENT3 likely has an additional crucial 322 role in viral replication and survival. contributes to maintaining lysosomal pH, implying its potential involvement in 336 virus uncoating. To test this possibility, we labeled viral RNA with Syto82 dye 337 (Hover et al, 2018) and allowed these viruses to infect target cells (Fig 7A) . 338 Comparing WT to ENT3 -/-BMDMs, we found that a substantial amount of EMCV 339 viral RNA was trapped in the ENT3 -/-BMDMs ( Fig 7B, yellow arrowheads) while 340 most of the viral RNA had entered and dissipated into the cytoplasm in the WT 341 BMDMs. These images were further quantified and revealed that a significantly 342 higher percentage of ENT3 -/-BMDMs were Syto82 positive ( Fig 7C) and were 343 with stronger signals compared to the WT group ( Fig 7D) . These results support 344 the notion that ENT3 has a vital role in the viral uncoating step. To further explore 345 the importance of ENT3 in viral replication, we included an additional virus strain, 346 SARS-CoV2, for testing. The ENT3 knockdown Calu-3 cells (human lung 347 epithelial cells) were generated using the lentiviral-shRNA system (Fig 7E) . To 348 examine if the presence of ENT3 affects the replication of SARS-CoV2, the 349 control, and ENT3 knockdown Calu-3 were infected with either SARS-CoV2 or 350 delta variant (B.1.617.2) and evaluated. We found that even ~ 50% of ENT3 351 knockdown significantly decreased the viral replication of both SARS-CoV2 (Fig 352 7F ) and delta variant (Fig 7G) judging by the viral RNA amount and plaque assay 353 (Supplemental Fig 4) . These results suggest ENT3 is a key component in viral 354 propagation and imply that modulating ENT3 expression could have therapeutic 355 This study unveils ENT3 as an early metabolic responder upon bacterial and viral 359 challenge. Through dissecting the signaling events regulating the expression of 360 ENT3, we also reveal that ENT3 is an ISG. Intriguingly, it is an ISG being taken 361 advantage of by a virus to facilitate its replication. These results demonstrate that 362 metabolic preparedness is a vital part of innate immunity and how pathogens 363 Mice 458 Wild type C57BL/6J mice were obtained from National Laboratory Animal Center, 459 Taiwan. ENT3 -/mice (Tang et al, 2010) were obtained from the Mutant Mouse week-old mice and treated with ACK buffer to remove erythrocytes. Cells were 487 cultured in complete DMEM at 37°C, 5% CO 2 for 1 hr. Non-adherent cells were 488 collected and cultured in complete DMEM supplemented with 10% L929 489 conditional medium at 37°C, 5% CO 2 for 6 days. The media were replenished 490 every 3 days. Mature BMDMs were harvested by 5 mM EDTA and rested at 491 37°C, 5% CO 2 overnight for before experiments. The shRNA lentiviral vectors targeting human ENT3 and a non-targeting control, 569 Total RNA was extracted by using TRI reagent (Invitrogen) following 592 manufacturer's protocol. Reverse transcription was performed by using 593 SuperScript III Reverse Transcriptase (Invitrogen) with oligo (dT) 20 (Invitrogen), 594 dNTP mix (Invitrogen), and RNaseOUT (Invitrogen). qPCR was performed on 595 StepOnePlus™ Real-Time PCR System (Applied Biosystems) by using Taqman 596 universal master mix (Applied Biosystems) with Taqman Gene Expression Assay 597 probe and primers (Thermo Fisher Scientific) or using iQ SYBR Green Supermix 598 (Bio-Rad) with the primers listed in Table S1 . The relative gene expression was 599 normalized to Rpl19 or RPLP0 by using the 2-ΔCt method. The fold change of 600 gene expression was normalized to unstimulated BMDMs (defined as 1) by using 601 the 2-ΔΔCt method. 602 603 ChIP assay was performed with SimpleChIP ® Enzymatic Chromatin IP Kit (Cell 605 Signaling Technology). In brief, BMDMs treated with 100 U/mL IFN-β for 4 hr 606 were fixed in 1 % formaldehyde for 10 min. Chromatin was fragmented by using 607 micrococcal nuclease (Cell Signaling Technology), and the cell membrane was 608 broken down by Bioruptor (Diagenode). 2% of samples were aliquoted for input controls, and the remaining samples were incubated with anti-STAT1 antibody 610 (Cell Signaling Technology) and control antibodies (Cell signaling Technology) 611 overnight at 4°C with rotation. The precipitated DNA was purified and conducted 612 qPCR assay by using iQ SYBR Green Supermix with the primers listed in Table 613 S1. The data were analyzed by the following formula: % of input = input dilution 614 factor/bound dilution factor) × 2(input CT−bound CT) × 100 and then normalized 615 to IgG control as 1. This work is funded by MOST 108-2628-B-010-005, 696 109-2628-B-010-016, 110-2628-B-A49A-510 and Cancer Progression Research supported 704 and provided multiple knockout mouse strains in the study. I.L.D., and C.-L.H. 705 conceptualized the study, designed and supervised the experiments 716 Coordination of ENT2-dependent adenosine transport and signaling 717 dampens mucosal inflammation An essential role for the Zn2+ transporter 722 ZIP7 in B cell development Functional Characterization of Novel Human and Mouse 724 Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in 725 Intracellular Membranes A mild form of SLC29A3 disorder: a frameshift deletion 729 leads to the paradoxical translation of an otherwise noncoding mRNA splice 730 variant Imaging poliovirus entry in live cells Whole-exome sequencing 735 identifies mutations in the nucleoside transporter gene SLC29A3 in 736 dysosteosclerosis, a form of osteopetrosis Mechanical Stiffness Controls Dendritic Cell Metabolism and Function Emerging concepts of T cell metabolism as a 744 target of immunotherapy Metabolic Competition in the Tumor Microenvironment Is a 748 Driver of Cancer Progression A type Flt3 ligand axis augments plasmacytoid dendritic cell development from 751 common lymphoid progenitors D614G Substitution of 755 SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer 756 via Enhanced Furin-Mediated Spike Cleavage SLC29A3 gene is mutated in 761 pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome 762 and interacts with the insulin signaling pathway Tanowitz 765 HB & Kuliawat R (2017) Alterations in pancreatic β cell function and 766 Trypanosoma cruzi infection: evidence from human and animal studies Targeted disruption of 769 the mouse Stat1 gene results in compromised innate immunity to viral 770 disease An Egyptian family with H syndrome due to a novel mutation in 773 SLC29A3 illustrating overlapping features with pigmented hypertrichotic 774 dermatosis with insulin-dependent diabetes and Faisalabad histiocytosis Metabolic Reprogramming of Macrophages: GLUCOSE TRANSPORTER 1 779 (GLUT1)-MEDIATED GLUCOSE METABOLISM DRIVES A 780 PROINFLAMMATORY PHENOTYPE Critical Role of Zinc Transporter (ZIP8) in Myeloid Innate Immune Cell 783 Function and the Host Response against Bacterial Pneumonia Toll-like Receptors Activate Innate and 786 Adaptive Immunity by using Dendritic Cell-Intrinsic and -Extrinsic 787 Mechanisms Bunyavirus requirement for endosomal K+ reveals new roles of 790 cellular ion channels during infection The 792 Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival Metabolite transporters-the gatekeepers for T 795 cell metabolism Nucleoside Transporter 3 Deficiency Perturbs Lysosome Function and 800 H syndrome: Clinical, histological 804 and genetic investigation in Tunisian patients Advances in the 806 development of nucleoside and nucleotide analogues for cancer and viral 807 diseases Metabolic reprogramming in macrophages and 809 dendritic cells in innate immunity Nutrient Transport and Pathogenesis in Selected Parasitic 811 Protozoa LPS/TLR4 signal transduction pathway Resistance of leukemia cells to cytarabine chemotherapy is mediated by 817 bone marrow stroma, involves cell-surface equilibrative nucleoside 818 transporter-1 removal and correlates with patient outcome Mutations in SLC29A3, encoding an 827 equilibrative nucleoside transporter ENT3, cause a familial histiocytosis 828 syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease Learning from the viral journey: how to enter 831 cells and how to overcome intracellular barriers to reach the nucleus Beedle AM & 835 Govindarajan R (2019) Adult stem cell deficits drive Slc29a3 disorders in 836 mice Immunometabolism governs dendritic cell and 838 macrophage function Mechanisms of type-I-and type-II-interferon-mediated 840 signalling H 842 syndrome: novel and recurrent mutations in SLC29A3 Virus life cycle. Molecular Virology of Human Pathogenic 845 Viruses Interferon-stimulated genes: a 847 complex web of host defenses bioRxiv YM2019 Nucleosides drive 849 histiocytosis in SLC29A3 disorders by activating TLR7. biorxiv.org Gene-expression profiling reveals down-regulation of 855 equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-856 derived cells A mouse knockout library 860 for secreted and transmembrane proteins Macrophages 863 and Metabolism in the Tumor Microenvironment Amino Acids and Their Transporters in T Cell Immunity 865 and Cancer Therapy Transcriptional 867 Regulation of Antiviral Interferon-Stimulated Genes Equilibrative Nucleoside 871 Transporter 3 Regulates T Cell Homeostasis by Coordinating Lysosomal 872 Function with Staphylococcus aureus targets 874 the purine salvage pathway to kill phagocytes Deletion of equilibrative 877 nucleoside transporter-2 protects against lipopolysaccharide-induced 878 neuroinflammation and blood-brain barrier dysfunction in mice The human 881 concentrative and equilibrative nucleoside transporter families, SLC28 and 882 SLC29 Molecular 884 Aspects of Medicine The 980 replication of EMCV in ENT3 -/-BMDMs were evaluated in the presence of 981 exogenous 1 or 10 µM of ribonucleosides (A, U, C, G) 9 hr post-infection. Shown 982 are combined results from three independent experiments (N=3). unpaired two-983 tailed Student's t-test was used for statistical analysis Figure 7. ENT3 supports the uncoating of virus, and the replication of SARS-CoV-2 requires functional ENT3. (A) Illustration of strategy to track the 987 viral uncoating upon infection. (B) WT and ENT3 -/-BMDMs were infected with Syto82-labeled EMCV (MOI=1) and subjected to live imagining at 30-, 60-and 989 90-min post-infection. The arrowheads indicated the Syto82 + virus puncta in the 990 cell. (C, D) Quantification of Syto82 signal in BMDMs at 60 min time point was 991 performed by enumerating Syto82 + cells (%) (C) and the mean fluorescent 992 intensity (MFI) per Syto82 + cell (D). Results were generated images from 3 993 independent experiments Student's t-test was used for statistical analysis, *p < 0.05. (E) ENT3 knockdown 995 in Calu-3 cells was performed by lentiviral shRNA system. The knockdown 996 efficiency was confirmed by RT-qPCR. The SLC29A3 expression level was 997 calculated relative to RPLP0 and normalized to scramble control as 1 ENT3 knockdown Calu-3 cells were infected with SARS-CoV-2 original strain (F) 999 or delta variant (G) at MOI=0.1 for 1 hr, and subjected for the viral replication 1000 analysis at 24 hr post-infection by RT-qPCR. The SARS-CoV-2 E gene 1001 expression level was calculated relative to Shown are combined results from three independent experiments (N=3) Unpaired two-tailed Student's t-test was used for statistical analysis were i.p. challenged with 10 7 PFU EMCV and sacrificed 3 days post-infection. 642For the viral load examination in brains, brain tissues were homogenized in 1 mL 643 PBS with plastic micro pestles, the supernatants were clarified by centrifugation 644 twice at 3,000 rpm, 4°C for 10 min, and the viral titer quantified by plaque assay 645 on Vero cells. 646 647 Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) 649were recorded using the Seahorse XFe24 system (Agilent Technologies), and all 650 procedures were performed following the manufacturer's protocol. Briefly, 651BMDMs from WT or ENT3 -/mice were seeded into XF24 culture microplate 652 (Agilent Technologies) and incubated at 37°C, 5% CO 2 overnight . Culture media 653were then replaced with complete DMEM without sodium pyruvate to evaluate 654 the respiratory capacity of cells; and the complete DMEM without sodium 655 pyruvate and glucose to measure the glycolysis capacity. After basal OCR or 656 ECAR measurements, sequential injection of 1 µM oligomycin A (Sigma-Aldrich), 657 2 µM FCCP (Sigma-Aldrich), and 0.5 µM Antimycin A (Sigma-Aldrich) were 658 applied for respiratory capacity measurements; 10 mM glucose, 1 µM oligomycin 659 A, and 50 mM 2-DG (Sigma-Aldrich) were used for glycolysis capacity 660 measurements. The parameters were recorded 3 times after each drug 661 projection. 662 BMDMs from WT or ENT3 -/mice were treated with 1000 U/mL IFN-β for 4 hr, 665 and the total RNA was extracted as described above. The RNA concentration 666 was measured by Qubit fluorometer with Quant-iT RNA BR assay kit. The RNA